$16.93
-1.5%Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Outstanding operational efficiency. The company generates substantial profit from core operations.
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
HQL โข NYSE
| Tekla Life Sciences Investors Income Statement | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | Sep 2008 | Sep 2007 | Sep 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
86.4M | 86.7M | 39.4M | 31.9M | 45M | 39.1M | 2.4M | 2M | 69.8M | 6.3M | 1.3M | 876.8K | 516.8K | 2.1M | 570K | 1.8M | 460K | 1.7M | 2.9M | 2.3M | |
GROSS PROFIT | ||||||||||||||||||||
(0.0) | (0.0) | (5.2M) | (5.5M) | (6.1M) | (5.2M) | (0.0) | (0.0) | (4.6M) | (4.9M) | (5.6M) | (4.1M) | (3.1M) | (2.5M) | (3M) | (3M) | (2.9M) | (3.8M) | (3.6M) | (2.9M) | |
86.4M | 86.7M | 18.3M | 26.3M | 38.9M | 33.9M | 2.4M | 2M | 65.2M | 1.3M | -4.3M | -3.3M | -2.6M | -335.5K | -2.5M | -1.2M | -2.4M | -2.1M | -740K | -630K | |
OPERATING INCOME | ||||||||||||||||||||
(791.6K) | (1.4M) | (1.2M) | (1.4M) | (1.2M) | (1M) | (5.3M) | (5.6M) | (1.3M) | (13.3M) | (39.2M) | (88.4M) | (84.1M) | (75.5M) | (1.4M) | (790K) | (760K) | (820K) | (970K) | (710K) | |
(743.2K) | (1.3M) | (903.1K) | (1.1M) | (844K) | (751.3K) | (5.3M) | (5.6M) | (991.5K) | -1.0 | (6M) | (4.6M) | (3.7M) | (3.4M) | (1.2M) | (630K) | (590K) | (680K) | (720K) | (550K) | |
(0.0) | (0.0) | (0.0) | -3.0 | (0.0) | (3.0) | (0.0) | (0.0) | (1.0) | -1.0 | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
85.6M | 85.3M | -5.2M | -104.6M | 64.5M | 123.1M | -2.9M | -3.6M | -3.9M | -3.8M | -4.7M | -3.8M | -3.2M | -1.3M | -3.8M | -2M | -3.2M | -2.9M | -1.7M | -1.3M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (45.2M) | (93M) | (87.8M) | (78.9M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
349.8K | 1M | 204.4K | 50.1K | 0.0 | 164.8K | 0.0 | 0.0 | 90.6K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(48.4K) | (56.7K) | (268.3K) | (276K) | (313.7K) | (278.7K) | (0.0) | (0.0) | (423.3K) | (20.7M) | (143.4K) | (130K) | (150K) | (200K) | (200K) | (160K) | (170K) | (140K) | (250K) | (160K) | |
0.0 | 87.2M | 27.6M | 2.4K | -7.8K | -11.2K | -67.6M | 32.3M | 72.7M | -8.1M | 45.2M | 93M | 87.8M | 78.9M | 41.3M | 12.2M | -18.5M | 63.2M | 52.2M | -20.1M | |
85.6M | 85.3M | 22.4M | -104.6M | 64.5M | 123.1M | -70.5M | 28.7M | 68.6M | -11.9M | 40.5M | 89.3M | 84.6M | 77.6M | 37.5M | 10.2M | -21.7M | 60.3M | 50.5M | -21.4M | |
NET INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
85.6M | 85.3M | 22.4M | -104.6M | 64.5M | 123.1M | -70.5M | 28.7M | 68.6M | -11.9M | 40.5M | 89.3M | 84.6M | 77.6M | 37.5M | 10.2M | -21.7M | 60.3M | 50.5M | -21.4M |
HQL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | April 22, 2024 | June 25, 2024 | 2024 | |
8-K 8-K 2023 N/A | September 12, 2023 | September 06, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | April 11, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 12, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2019 N/A | April 15, 2019 | June 13, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 18, 2018 | June 14, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 18, 2017 | June 15, 2017 | 2017 | |
DEF 14A DEF 14A 2014 N/A | April 30, 2014 | June 09, 2014 | 2014 | |
DEF 14A DEF 14A 2013 N/A | April 25, 2013 | June 04, 2013 | 2013 | |
8-K 8-K 2013 N/A | March 25, 2013 | March 22, 2013 | 2013 |
Continue your HQL research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.